AbCellera Biologics Inc.
ABCLNasdaq
$6.47
↑ +5.0%Jul 17 close · end-of-day
Price
1Y↑ +59.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.0B
Enterprise Value
$1.9B
P/E
—
P/S
24.7
P/B
2.1
EV/EBITDA
—
PEG
—
FCF Yield
-9.7%
Dividend Yield
—
Revenue (TTM)
$79.2M
Net Income (TTM)
-$144.0M
Free Cash Flow (TTM)
-$189.2M
Gross Margin
—
Operating Margin
-267.6%
Net Margin
-181.7%
ROE
-15.3%
ROIC
-19.4%
Debt / Equity
—
Net Cash
$77.1M
Return 1Y
+65.8%
Company profile
AbCellera Biologics Inc. has 156 discovery programs that are either completed, in progress, or under contract with 36 partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
- CEO
- Carl Lars G. Hansen
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 500
- Headquarters
- British Columbia
- Website
- abcellera.com
Earnings
ABCL Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$8.3M↑ +96.3%
Diluted EPS-$0.14↓ -6.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $233.2M | $375.2M | $485.4M | $38.0M | $28.8M | $75.1M |
| Gross profit | — | — | — | — | — | — |
| Operating income | $156.0M | $204.4M | $216.5M | -$237.2M | -$314.8M | -$217.1M |
| Net income | $118.9M | $153.5M | $158.5M | -$146.4M | -$162.9M | -$146.4M |
| Diluted EPS | $0.45 | $0.48 | $0.50 | -$0.51 | -$0.55 | -$0.49 |
| Operating cash flow | $22.7M | $244.6M | $277.4M | -$43.9M | -$108.6M | -$131.3M |
| Free cash flow | $13.0M | $186.1M | $206.7M | -$120.8M | -$187.0M | -$174.1M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 66.9% | 54.5% | 44.6% | -623.8% | -1091.7% | -289.0% |
| Net margin | 51.0% | 40.9% | 32.7% | -385.0% | -564.8% | -194.9% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.3M | $6.5M | $5.0M | $4.2M | $17.1M | $9.0M | $44.9M | $8.3M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$93.5M | -$93.7M | -$72.8M | -$62.7M | -$49.6M | -$76.3M | -$28.6M | -$57.5M |
| Net income | -$36.9M | -$51.1M | -$34.2M | -$45.6M | -$34.7M | -$57.1M | -$8.9M | -$43.2M |
| Diluted EPS | -$0.13 | -$0.17 | -$0.11 | -$0.15 | -$0.12 | -$0.19 | -$0.03 | -$0.14 |
| Operating cash flow | -$30.0M | -$28.9M | -$8.0M | -$11.6M | -$32.4M | -$52.6M | -$34.7M | -$33.5M |
| Free cash flow | -$50.1M | -$47.4M | -$23.6M | -$22.2M | -$45.8M | -$61.5M | -$44.6M | -$37.4M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -1276.2% | -1439.4% | -1441.0% | -1479.6% | -290.2% | -851.8% | -63.7% | -691.7% |
| Net margin | -504.3% | -785.4% | -677.6% | -1077.2% | -203.3% | -637.8% | -19.9% | -519.1% |
Company news
Jul 7, 2026
Jul 3, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-03 | Booth Andrew· Chief Financial Officer | Option exercise | 250,000 | $0.19 | $47,500.00 | filing |
| 2026-05-14 | Montalbano John S. | Buy | 20,000 | $4.77 | $95,400.00 | filing |
| 2026-02-27 | Booth Andrew· Chief Financial Officer | Buy | 42,600 | $3.42 | $145,692.00 | filing |
| 2026-02-27 | Thermopylae Holdings Ltd. | Buy | 38,000 | $3.44 | $130,720.00 | filing |
| 2026-02-26 | Thermopylae Holdings Ltd. | Buy | 177,457 | $3.27 | $580,284.39 | filing |
| 2025-12-18 | Thermopylae Holdings Ltd. | Gift | 225,000 | $0.00 | $0.00 | filing |
| 2025-11-26 | Montalbano John S. | Buy | 50,000 | $3.57 | $178,460.00 | filing |
Latest 7 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.